Praxis Precision Medicines, Inc. ((PRAX)) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Praxis Precision Medicines, Inc. is conducting a clinical study titled ‘A Double-Blind, Randomized, Multicenter, Trial Evaluating the Efficacy and Safety of PRAX-628 in Adults With Focal Seizures (POWER1)’. The study aims to assess the effectiveness and safety of PRAX-628 in treating adults with focal seizures, a condition characterized by localized brain activity leading to seizures. This research is significant as it could offer a new therapeutic option for patients with limited treatment choices.
The study is testing PRAX-628, an oral drug administered once daily. Participants receive 20 mg per day for the first six weeks, followed by 30 mg per day for the remaining six weeks. The study also includes a placebo group for comparison.
This interventional study follows a randomized, parallel assignment model with quadruple masking, meaning that participants, care providers, investigators, and outcomes assessors are blinded to the treatment allocations. The primary purpose of the study is treatment-focused.
The study began on March 14, 2025, with the latest update submitted on May 23, 2025. These dates are crucial as they indicate the study’s progression and the timeliness of the data being collected.
The update on this study could influence Praxis Precision Medicines’ stock performance positively if the results show PRAX-628 to be effective and safe. Investors might view this as a promising development, potentially increasing interest and investment in the company. Competitors in the epilepsy treatment market will likely monitor these developments closely.
The study is currently recruiting, with further details available on the ClinicalTrials portal.